RNS Number: 4780K

Maven Income and Growth VCT 3 PLC

25 August 2023

## Maven Income and Growth VCT 3 PLC

## Issue of Equity - Dividend Investment Scheme

The Board of Maven Income and Growth VCT 3 PLC (the Company) confirms that, on 25 August 2023 and under its Dividend Investment Scheme (DIS), the Company issued and allotted 121,694 new ordinary shares of 10p each (Ordinary Shares) at a price of 53.12p per share which, under the Terms and Conditions of the DIS, is equivalent to the latest announced net asset value per share.

As a result, and in accordance with the Financial Conduct Authority's Disclosure, Guidance and Transparency Rules, the Company confirms that its issued share capital as at 25 August 2023 comprises 114,720,327 Ordinary Shares, with each share carrying one voting right. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required, under the Disclosure, Guidance and Transparency Rules, to notify their interest, or a change to their interest, in the Company.

Application will be made to the FCA and the London Stock Exchange for the new Ordinary Shares issued under the DIS to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that admission will become effective and dealings will commence on, or around, 31 August 2023.

Issued on behalf of the Board

Maven Capital Partners UK LLP Secretary

25 August 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:msc.com">msc.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

**IOEFIFVTTDIEFIV**